APR 1·Stock Titan▲
Rinzimetostat Phase 3 dose and cash runway update from ORIC (NASDAQ: ORIC)
ORIC Pharmaceuticals announced it is advancing rinzimetostat (ORIC-944) to Phase 3 at a 400 mg once-daily dose in combination with darolutamide for metastatic castration-resistant prostate cancer, based on favorable efficacy and a differentiated safety profile from Phase 1b optimization data. The company reported strong PSA responses and a good tolerability profile at this dose, with fewer adverse events and dose modifications compared to higher doses or competitor regimens. ORIC also updated its financial position, showing approximately $412 million in cash and investments, providing a cash runway into the second half of 2028, sufficient to execute planned registrational trials for rinzimetostat and another late-stage candidate, enozertinib.
MAR 15·MarketBeat→
Oric Pharmaceuticals, Inc. $ORIC Position Reduced by ArrowMark Colorado Holdings LLC
ArrowMark Colorado Holdings LLC recently reduced its stake in Oric Pharmaceuticals (NASDAQ:ORIC) by 14.2% in the third quarter, selling 180,957 shares and retaining over 1 million shares valued at approximately $13.17 million. This move comes as company insiders have also been net sellers, with CEO Jacob Chacko and another insider selling shares totaling over $1.20 million in the past three months. Despite insider selling, analysts maintain a "Moderate Buy" consensus and a price target of $20.20 for ORIC, which is currently trading around $11.90.
